




The Future of **Skin rejuvenation laser treatment**

Revolutionary versatile technology,
Ultra small spots,
Narrowest ablative micro-tunnels,
Wide coagulation,
Low pain, Low downtime,
Safe, All skin types.



The non-invasive aesthetic treatment market is booming

Here's why



Zoom Effect

Consumers are spending more time **looking at their reflections** - video calls have permanently changed how we view ourselves.



Shift Away

Aesthetic lasers are quickly replacing plastic surgery for their quick recovery and minimal discomfort.



Male and Young Clients

Aesthetic procedures are in high demand among men. Aesthetic medicine offers subtle tweaks instead of dramatic procedures.

*** <https://www.visionresearchreports.com/non-invasive-aesthetic-treatment-market/39012>



For non-invasive treatments,
Lasers are leading the way



Aesthetic laser treatments are among the **most lucrative services** in the non-invasive sector



There are **5 major issues** with the current laser treatments



5 major issues with current lasers

1

OVERSATURATED

Me too options

2

OVERSPECIALIZED

Specialized lasers
for each problem

- ✖ Wrinkles
- ✖ Scars
- ✖ Pigmentation-reducing
- ✖ Cost-effectiveness



5 major issues with current lasers

3

MULTIPLE
SIDE EFFECTS



Side Effects

- ✖ Scarring
- ✖ Burns
- ✖ Pain
- ✖ Infection
- ✖ Hypopigmentation
- ✖ PIH (Post Inflammatory Hyperpigmentation)



5 major issues with current lasers

4

BARRIERS FOR PEOPLE OF COLOR

50%
of potential patients of color
can't receive best treatment



5 major issues with current lasers

5

LONG DOWNTIME -
UP TO 2 WEEKS!



Epicare novel technology

Specifications

Property	1940 nm	Low power / High efficacy aspect
Wavelength	1.8 W	
Average Power	12 ns	Small footprint
Pulse Duration	1.8 mJ	
Pulse Energy	150 KW	
Peak Power	1 KHz	
Repetition Rate	40 μ m	No need for water cooling
Laser Spot size		



Outshines the competition

Max results. Min discomfort. Min downtime.

Laser Machine

Coagulation

BETTER



Epicare

Hemostasis to 300%
Controlled while lase

Spot size

SMALLER



40µm

Downtime less than 4 days

Max power

2 Watt

Er-Yag

From 0+ to <<30%

170µm

10Watt

CO2

30%

120µm

60Watt



Fotona SP Dynamis
2,940 nm Er:YAG



UltraPulse,
10,600 nm
CO2

Controlled Coagulation

Short downtime

Fraxel re:store
1550 nm
Erbium



Our vision: All-in-One

One platform for multiple indications with minimal downtime and maximum patient comfort

Indication:

Wrinkles
Rejuvenation
Pigmentation
Acne Scarring
Tightening

Scars

All skin types



Introducing


Epicare's Breakthrough Technology

One Laser. Endless Solutions.

LASERTEAM




- Many fast and high-power laser pulses
- On the same spot.
- With or without peripheral thermal effect




The ability to achieve a wider coagulation density, while performing less epidermis damage

CO2 Technologies



Long Pulse



Epicare treatment modes

Mode “Coagulative”

The Epicare's coagulative mode creates **narrow ablation micro-tunnels** (black arrow) surrounded by **wide coagulation zones** (Orange Zone). At the **15% maximum density** (based on ~350 μm coagulation width), the ablation portion is **under 1.5%**, giving an ablation-to-coagulation ratio of ~0.1. This mode is **less painful, less bleeding**, and the **epidermis closes within 24 hours**.

Unlike conventional non-ablative lasers, the coagulation is produced by **uniform depth heating** (not tied to the absorption curve), and heat **does not extend much beyond the coagulated tissue**.




Epicare treatment modes

Mode “Ablative”


The Epicare's ablative mode creates **narrow ablation micro-tunnels** (black arrow) with **narrow surrounding coagulation (Orange Zone)**. At the **8% maximum density** (based on $\sim 150 \mu\text{m}$ coagulation width), the ablation area is **$\sim 3.5\%$** , giving an ablation-to-coagulation ratio of **~ 0.8** .

The **microtunnels are much narrower** than CO₂ lasers, with a **similar ablation/coagulation ratio**.



Histological comparison

Actual Coagulation width




High coagulation microcolumns
at various energies


300% coagulation

Ultra Narrow Spots

LASERTEAM



CO2 Technologies



A side-by-side comparison
between our low-frequency
operation and the CO2RE
ablation with the same scale





Proven efficacy in published studies Lasers in Surgery and Medicine

PRECLINICAL STUDY OPEN ACCESS

Evaluation of a Novel Ablative 1940 nm Pulsed Laser for Skin Rejuvenation

Yoav Gronovich¹  | Yaniv Raderman¹ | Ronen Toledo¹ | Rotem Nahear² | Neria Suliman² | Alon Shacham^{2,3} | David Fridman² | Salman Noach^{2,4}

¹Plastic and Reconstructive Surgery Department, Shaare Zedek Medical Center, Jerusalem, Israel | ²Laser Team Medical Ltd, Jerusalem, Israel | ³Department of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel | ⁴Faculty of Applied Physics, Electro-Optics Engineering Faculty, Jerusalem College of Technology, Jerusalem, Israel

Correspondence: Yoav Gronovich (yoavgg@gmail.com)

Received: 18 February 2024 | Revised: 29 May 2024 | Accepted: 18 June 2024

Keywords: 1940 nm | ablative | laser | resurfacing | skin rejuvenation

PRECLINICAL STUDY OPEN ACCESS

Safety Assessment of a 1940 nm Tm:YAP Laser for Fractional Skin Ablation in a Swine Model

Yuval Ramot^{1,2}  | Michal Steiner³ | Udi Vazana⁴ | Rotem Nahear⁵ | Neria Suliman⁵ | David J. Friedman⁵ | Salman Noach^{5,6} | Abraham Nyska⁷

¹Department of Dermatology, Hadassah Medical Center, Jerusalem, Israel | ²The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel | ³Preclinical Consultant, Rehovot, Israel | ⁴LAHAV CRO, Kibbutz Lahav, Israel | ⁵Laser Team Medical Ltd., Jerusalem, Israel | ⁶Department of Applied Physics, Electro-Optics Engineering Faculty, Jerusalem College of Technology, Jerusalem, Israel | ⁷Consultant in Toxicologic Pathology, Tel Aviv University, Tel Aviv, Israel

Correspondence: Abraham Nyska (anyska@nyska.net)

Received: 23 February 2025 | Revised: 11 April 2025 | Accepted: 18 April 2025

Funding: The study was funded by LaserTeam Ltd., Jerusalem, Israel and supported by the Israel Innovation Authority (Grant No. 73276).

Keywords: 1940 nm laser | collagen remodeling | dermatologic applications | epidermal regeneration | fractional laser ablation | histopathology | laser safety and efficacy | skin resurfacing | swine model | thulium-doped yttrium aluminum perovskite (Tm:YAP)



Granted Patents

Pending Patents

2µm Q-SWITCH Technology

Enable to achieve high energy pulses in nanosecond regime

Status: GRANTED

Filing date: April 2, 2018

[Granted US Patent No. 10,978,850](#)



1.7 to 3µm Tunable Q-Switch Technology

Enable to achieve different wavelengths of high energy pulses in nanosecond regime with a tunable spectral range of at least 20 nm;

Status: GRANTED

Filing date: May 22, 2019

[Granted US Patent No. 11,791,602](#)



Precise control over laser medical treatments

Enable to achieve Different controlled depth and different controlled coagulation width on a human tissue (skin)

Status: PENDING - National phase
(US; China; European patent office; Korea)

Filing date: Aug 29, 2023

[Pending PCT Application No. PCT/IL2023/050915](#)



Special laser pulse scanning to achieve fast treatment

Enable to achieve ultra fast treatment on treated area

Status: PENDING PCT

Filing date: Jan 25, 2024

[Pending PCT Application No. PCT/IL2024/050100](#)



Future applications and markets



Gynecology

Vaginal
rejuvenation
and more




Ophthalmology



ENT

Middle ear surgery,
stapedotomy
Laryngeal cancer,
and more



Brain Surgery




Drug Delivery


Enhanced trans
dermal drug
delivery



Company history




Roadmap (9/24 – 9/27)



Regulatory pathway to market success

Executed by Hogan Lovells US LLP and BioVision Ltd.



1

2

3

4

Pre-Submission meeting, to obtain the FDA's early feedback on the proposed regulatory strategy:

Indications for Use: The Epicare System is indicated for dermatological procedures requiring ablation, coagulation and resurfacing of soft tissue for the treatment of wrinkles.

Predicate and Reference devices:

- Primary Predicate: LASEMD Laser System (K171009)
- Reference Device: Syneron Medical Ltd. CO2RE (K151655)

GLP Animal Study: evaluation of the Safety and Efficacy of the Epicare System in Performing Fractional Skin Ablation in a Swine Model

Clinical Study: A Prospective, Interventional, Study for the Assessment of the Safety and Efficacy of Epicare for the Treatment of Periorbital Wrinkles



MARKET SUMMARY

Reflecting newest trends, consumer behavior, and energy-device market shifts

- Skin rejuvenation with fast, visible results and **minimal downtime** is now the #1 unmet need, especially among Millennials.
- Demand for **ongoing anti-aging treatments** continues to rise, driven by **preventive care** and earlier adoption.
- Existing technologies still have major limitations, especially for Asian, Hispanic, Middle Eastern, and darker skin tones, increasing demand for **safer alternatives**.
- Premium rejuvenation devices continue to command the highest physician fees, and the market is willing to **pay more for superior outcomes**.
- Demand for **full-body rejuvenation** is rising, including hands, neck, chest, and off-face pigmentation.
- Clinics are aggressively replacing older CO₂ systems, **seeking technologies that offer CO₂-level outcomes with dramatically lower downtime** and lower PIH risk.



Raising \$10M (2026 – 2028)

Marketing & regulations (5 M)

Regulatory submissions (1M): CE, CFDA

NEW indication, Clinical trials and Regulatory submissions (total: 2M):

Tightening, Rejuvenation, Pigmentation, Acne Scarring, Scars, for all skin types

PR campaigns (0.5M)

Build stock, Sales & Distribution force and KOL's (1.5M)

R&D + Engineering (2 M)

Next generation product:

Articulated Arm transition to fiber (0.5M)

Higher energy laser development (0.5M)

Cost reduction project (1M)

Decrease BOM from

New Articulated Arm

Injection molds for plastic parts and sand casting

Dedicated electronics and firmware

G&A + IP (3M)

IP worldwide (0.5M)

G&A for 3 years (2.5M)

Our team

is a collection of engineers and medical doctors who understand the market and its needs



CEO

Pini Ben Elazar, MBA

Veteran CEO in healthcare, led Mor Research applications, TTO of Clalit for 20 years.

Founded more than 80 startup companies.



CTO & CO-Founder

Prof. Salman Noach

Veteran CTO with 25 years of experience, inventor and founder of the 2µm solid-state laser lab at JCT, a faculty member at the physics department at JCT.



CMO

Dr. David J. Friedman, MD.

Expert in non-surgical aesthetic and laser dermatology, with extensive experience in clinical trials and training.


US Board Certified Dermatologist in the US and Israel. Former Assistant Professor at Brown. Medical Director of Candela Israel and Physician Trainer at Allergan Israel.



COO

Avi Mendelson, B.Sc.

Over 25 years of senior management in R&D and operations within startup and leading Medical Device companies (Lumenis, Candela)



Scientific advisory board



Dr. Jeffrey S. Dover, MD

A former Associate Professor of Dermatology at Harvard Medical School, he is the author of over 550 scientific publications and has co-authored and edited over 55 textbooks. Dr. Dover is the past president of the American Society for Lasers in Medicine and Surgery, the American Society for Dermatologic Surgery, and the New England Dermatology Society.



Dr. Sarit Cohen, MD

Head of the Israeli Center of Facial Sculpting, specializes in invasive and minimally invasive facial aesthetic procedures. Board-certified in plastic, reconstructive, and aesthetic surgery, she is a consultant for leading aesthetic companies and has published extensively on facial and body procedures.




Dr. Paul M. Friedman, MD

Director of Dermatology & Laser Surgery Center in Houston. Board-certified in dermatology, he trained at NYU and completed a fellowship in dermatologic and Mohs surgery. He is recognized globally for his advancements in dermatologic laser treatments.



Dr. Yakir Levin, MD, PhD

An Assistant Professor of Dermatology at Harvard Medical School and is a physician-scientist at the Massachusetts General Hospital. He maintains an active clinical practice at MGH's acclaimed Laser and Cosmetic Center and a significant research portfolio at its world-renowned Wellman Center for Photomedicine. He subspecializes in aesthetic dermatology and in the treatment of disfiguring birthmarks in children and conducts human and preclinical research studies geared toward improving these treatments.





Invest in Epicare

The game-changing innovation the laser market has been waiting for!

Thank You!

pinib@lasertm.com

